Navigation Links
XGEVA® (Denosumab) Granted Marketing Authorization in the European Union
Date:7/15/2011

THOUSAND OAKS, Calif., July 15, 2011 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that the European Commission (EC) has granted marketing authorization for XGEVA® (denosumab) for the prevention of skeletal-related events (SREs) (pathological fracture, radiation to bone, spinal cord compression or surgery to bone) in adults with bone metastases from solid tumors. This approval of XGEVA applies to all 27 European Union (EU) member states. The EC also granted XGEVA an additional year of data and market exclusivity in the EU since the indication was considered new for denosumab and based on the significant clinical benefit of XGEVA in comparison with existing therapies.

Bone metastases, the spread of cancer to the bones, are a common and serious concern for patients with advanced cancer and present a burden to the healthcare system. Weakened bones due to metastases can lead to SREs. The primary goal of treatment for bone metastases is to prevent the occurrence of these debilitating and costly SREs.

"Skeletal-related events associated with bone metastases are truly devastating and painful for patients living with cancer, and today's approval of XGEVA marks a real advance," said Professor Ingo J. Diel, M.D., Institute for Gynecological Oncology, SPGO, Mannheim, Germany. "In clinical trials XGEVA demonstrated sustained protection from SREs and also delayed the progression of pain. These factors will make a genuine difference in the lives of patients living with advanced cancer."

The marketing authorization for XGEVA is based on three pivotal, Phase 3 head-to-head trials that evaluated the effectiveness of XGEVA versus zoledronic acid at delaying SREs. The SRE clinical program for XGEVA spanned more than 50 tumor types in over 5,700 patients. In the SRE trials, XGEVA demonstrated a clinically meaningful improvement in preventing SREs compared to zoledronic acid. In these trials, XGEVA was administered every four weeks as a 120 mg subcu
'/>"/>

SOURCE Amgen
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Amgen Receives CHMP Positive Opinion for XGEVA™ (Denosumab) in the European Union
2. Treatment With Prolia® (denosumab) Associated With Significantly Greater Adherence, Compliance and Persistence Compared to Alendronate
3. Prolia® (denosumab) Open-Label Extension Trial Showed Continued Increase in Bone Mineral Density Over Five Years of Treatment With Similar Safety Profile Observed in Pivotal Trial
4. Results Published in The Lancet Demonstrate Superiority of XGEVA™ (Denosumab) in the Prevention of Bone Complications for Men With Bone Metastases From Advanced Prostate Cancer
5. The Journal of Clinical Oncology Publishes Phase 3 XGEVA™ (Denosumab) Results in Advanced Cancer Patients With Solid Tumors or Multiple Myeloma
6. XGEVA™ (Denosumab) Significantly Improved Bone Metastasis-Free Survival in Men With Prostate Cancer
7. Amgen Presents New XGEVA™ (Denosumab) Breast Cancer Skeletal-Related Event Prevention Data at SABCS
8. Prolia™ (denosumab) Receives Best New Drug Honor at Scrip Awards
9. China Botanic Pharmaceutical Granted China Patent for Siberian Ginseng Extraction Process
10. ACT Granted EU Orphan Medicinal Product Designation for hESC-Derived RPE Cells for Treatment of Stargardts Disease
11. ViroPharmas Cinryze® (C1 Inhibitor [Human]) Granted European Marketing Authorization for Hereditary Angioedema (HAE)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... Aug. 3, 2015 Par Pharmaceutical Companies, Inc. ... on Friday, August 7, 2015 at 9:00 a.m. EDT ... quarter ended June 30, 2015.  Par is privately held ... public in its filings with the Securities and Exchange ... its website by following the instructions at http://www.parpharm.com/financialinfo ...
(Date:8/3/2015)... 3, 2015 Ortho Clinical Diagnostics (OCD) today ... Chief Corporate Brand and Communications Officer, effective immediately. As ... Bouryal will lead the company,s worldwide corporate brand and ... to an independent company by adding sites in countries ... Chief Executive Officer Dr. Martin Madaus . ...
(Date:8/3/2015)... 2015 According to a ... "Global Market Study on Physiotherapy Equipment - ... by 2022", the global physiotherapy equipment market is estimated to ... 2015 and is expected to grow at a ... account for US$23.7 Bn by 2022. View ...
Breaking Medicine Technology:Ortho Clinical Diagnostics Appoints Kristie Bouryal Chief Corporate Brand and Communications Officer 2Global Physiotherapy Equipment Market Will Reach US$ 23.7 Billion by 2022: Persistence Market Research 2Global Physiotherapy Equipment Market Will Reach US$ 23.7 Billion by 2022: Persistence Market Research 3Global Physiotherapy Equipment Market Will Reach US$ 23.7 Billion by 2022: Persistence Market Research 4
... TROY, Mich., Oct. 25, 2011 CareTech Solutions, an ... for over 180 U.S. hospitals announced today that the ... information officer, Detroit Medical Center (DMC), Vanguard Health System ... the 2011 College of Health Information Management Executives (CHIME) ...
... Joseph F. Finn, Jr., C.P.A. ("Finn") Assignee for the ... today the contractual agreements for S1P1 lead compounds, AMG ... a sealed bid sale.   AMG-369, AMG-277 ... as part of License Agreement between Amgen and Epix ...
Cached Medicine Technology:Detroit Medical Center Shares Smart Room Case Study at CHIME 2011 Fall CIO Forum 2Contractual Agreements Revealed for S1P1 Lead Compounds, AMG 369 and AMG 277, Offered for Sale at a December 8, 2011 Sealed Bid Sale 2
(Date:8/3/2015)... ... August 03, 2015 , ... ... to Seattle-based Genelex to offer pharmacogenetic lab testing and precision medicine solutions that ... care costs. , Annually, more than 8.6 million adverse drug events are ...
(Date:8/3/2015)... ... August 03, 2015 , ... Dental practice in ... patients in need. Most people know that general health emergencies, such as broken arms ... amount of people know where to turn to during a dental emergency. This is ...
(Date:8/3/2015)... Florida (PRWEB) , ... August 03, 2015 , ... ... for Physician Leadership ® and Navigant Center for Healthcare Research and Policy Analysis ... , Fifty-five percent of respondents said they agreed or strongly agreed that the ...
(Date:8/3/2015)... ... , ... The U.S. Food and Drug Administration (FDA) recently approved a new ... which occurs naturally in the body and helps absorb and breakdown fat cells. Previously, ... body. These are invasive procedures and very expensive for most people. Now with Kybella, ...
(Date:8/3/2015)... ... ... Illinois Health & Science (IHS) has completed the purchase of IBA Molecular ... IBAM NA’s cyclotron sites and research and development facilities. , “We are ... as a large manufacturing hub in Noblesville, Indiana,” said Ken Smithmier, President and CEO ...
Breaking Medicine News(10 mins):Health News:Novation Awards Genelex First Group Purchasing Agreement for Pharmacogenetic Testing and Precision Medicine Software 2Health News:Novation Awards Genelex First Group Purchasing Agreement for Pharmacogenetic Testing and Precision Medicine Software 3Health News:Los Angeles Dental Practice, Sunset Plaza Dental, Now Offers Emergency Dental Services 2Health News:Los Angeles Dental Practice, Sunset Plaza Dental, Now Offers Emergency Dental Services 3Health News:Survey Finds Support for the Affordable Care Act Among Physician Leaders 2Health News:Survey Finds Support for the Affordable Care Act Among Physician Leaders 3Health News:Dr. Ava Shamban to Offer the New Double Chin Treatment Kybella 2Health News:Dr. Ava Shamban to Offer the New Double Chin Treatment Kybella 3Health News:Illinois Health & Science Expands Nuclear Medicine Footprint With Purchase of IBA Molecular North America, Inc. 2
... research suggests that the patients who undergo surgery to ... later developing pancreatic cancer. The investigators base their findings ... operation known as gastrectomy to remove their ulcers.// ... the stomach or a portion of the small intestine, ...
... has sex and any subsequent risk of birth defects such ... of sex might increase the risk of birth defects in ... and gynecology at Baylor College of Medicine in Houston told ... known causes of birth defects in lower animals. ...
... The government approved a long-awaited treatment for lymphoma - ... radiation directly to cancer cells. Idec Pharmaceuticals' Zevalin becomes ... US. // ,It's a new approach, adding ... CD20 found on lymphoma cells. The antibodies attach to ...
... group have developed an efficient method of identifying strains ... diseases such as meningococcal disease. The Cooperative ... Technology (QUT) has taken advantage of two new technologies// ... recently - DNA chip technology and comparative gene sequence ...
... which could make gene therapy powerful. The advance which is ... the modified genes to slip right into the cell nucleus.A ... an entire human.// ,This means that the DNA molecule ... smuggle or slip their modified DNA strands into the cells ...
... to a new study, filtering out the antibodies that can ... live donor transplants. Many patients need a kidney transplant but ... Body organs, from dead bodies, are in short supply, and ... must be of a compatible blood group. ,But ...
Cached Medicine News:Health News:Ulcer Surgery connected to danger of Pancreatic Cancer 2Health News:Identifying bacteria made amiable 2
... Oxygen Conservation Device. Bypass ... ,6200 Accessories: , OCD870C ... CGA 540 Regulator , OCD2001-18 ... Booklet , CP2140 Vertical M-6 ...
... Catheter with Accutrol is similar in design ... that it incorporates a temperature probe at ... temperature probe can accurately determine the patient's ... provides temperature accuracy comparable to a pulmonary ...
... These markers are available with 16 or 24 ... 6.5mm diameter, and an outer 9.5mm diameter. The markers ... in one single step for a 16 or 24 ... outer points on the cornea to achieve a precise ...
... Through A 1.0mm Incision., ,Special Direct Acting ... Improved ... Approach., ,Recessed Jaws For Improved Sub-Incisional Flap ... Jaws During Sterilization., ,Reusable, Autoclaveable, Guaranteed For ...
Medicine Products: